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Background
Agitation is an urgent condition involving motor hyperac-
tivity and a common manifestation of various underlying
psychopathological conditions, including schizophrenia
and bipolar disorder [1]. The primary purpose of this
observational study was to describe the occurrence of EPS
and secondary to describe the course of agitation during a
24-hour period, in patients with schizophrenia and bipo-
lar disorder with associated acute agitation treated with
IM psychotropic therapies.
Materials and methods
In this multicenter, prospective, observational study were
included acutely agitated patients with schizophrenia or
bipolar disorder who required treatment with at least one
injection of an IM psychotropic drug. Therapies were cho-
sen by the clinician. EPS were recorded as reported epi-
sodes of acute dystonia, akathisia and Parkinsonism. The
course of agitation symptoms was studied with the use of
CGI-S (Clinical Global Impression of Severity), CGI-I
(Clinical Global Impression of Improvement) and
PANSS-EC (Positive and Negative Syndrome Scale-
Excited Component). The present analysis only included
patients from the Greek cohort. Patterns of prescription
are described.
Results
A total of 1945 patients were included from 12 European
countries, the Greek cohort consisted of 300 patients, who
completed the 24-hour period. Two post-hoc therapies
cohorts were analyzed: olanzapine IM (120 patients) and
other IM (180 patients). EPS were described in 11.3% of
the patients. 51.7% of the patients received anticholiner-
gic medication in the 24-hour period following IM injec-
tion (20.8% for the olanzapine IM and 72.2% for the
other IM cohort). Both cohorts showed improvement in
agitation symptoms at 1 and 24 hours after baseline injec-
tion as shown in the ratings of CGI-S (mean overall CGI-
S decrease: 0.9 and 1.6 respectively), CGI-I (mean overall
CGI-I: 2.7 and 2.3 respectively) and PANSS-EC (mean
overall Total PANSS-EC decrease: 5.8 and 8.8 respec-
tively).
Conclusions
IM psychotropic therapies appeared to be well tolerated
for the treatment of acute agitation in patients with schiz-
ophrenia and bipolar disorder. Moreover, patients treated
with IM psychotropics (olanzapine and other IM) showed
improvement in agitation measures, after 1 and 24 hours.
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